New antibiotic candidate BWC0977 enters first human safety trial
NCT ID NCT07029932
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests the safety and how the body handles a new antibiotic called BWC0977. It involves 48 healthy adults aged 18 to 55 who will receive either the drug or a placebo by IV. The goal is to find safe doses for future studies targeting drug-resistant bacterial infections.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTIMICROBIAL DRUG RESISTANCE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Nucleus Network
RECRUITINGMelbourne, Victoria, 3004, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Putting dietitians in charge of hospital nutrition: a recipe for shorter stays?
- 23,000 seniors join study to unlock secrets of aging and infection
- Cash for breastfeeding: a new way to boost baby health?
- New shingles vaccine shows promise in Head-to-Head trial
- Can a simple letter curb antibiotic overuse? BC study aims to find out
- Awe-Inspiring nature game may boost vaccination and Mask-Wearing